Si-bone, Inc. income statement
In fiscal 2025, Si-bone, Inc. reported revenue of $201m, up 20.2% on the year before, operating income of −$22.3m (a -11.1% margin) and net income of −$18.9m, or −$0.44 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48 | 55 | 67 | 73 | 90 | 106 | 139 | 167 | 201 | 214 |
| Cost of revenue | 5 | 5 | 7 | 9 | 10 | 16 | 29 | 35 | 41 | 44 |
| Gross profit | 43 | 51 | 61 | 64 | 80 | 91 | 109 | 132 | 160 | 170 |
| Research and development | 6 | 5 | 7 | 9 | 12 | 14 | 15 | 17 | 17 | 18 |
| Selling and marketing | 42 | 44 | 68 | 74 | 94 | 108 | 110 | 117 | 124 | 130 |
| General and administrative | 13 | 13 | 21 | 20 | 25 | 29 | 31 | 34 | 41 | 40 |
| Operating income | −17 | −12 | −36 | −39 | −52 | −60 | −47 | −35 | −22 | −18 |
| Interest expense | 6 | 5 | 5 | 6 | 5 | 3 | 3 | 3 | 3 | 2 |
| Income before tax | −23 | −17 | −38 | −44 | — | — | — | — | — | — |
| Income tax | 0 | 0 | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −23 | −17 | −38 | −44 | −57 | −61 | −43 | −31 | −19 | −15 |
| Diluted EPS | −$2.22 | −$0.73 | −$1.55 | −$1.50 | −$1.71 | −$1.79 | −$1.13 | −$0.75 | −$0.44 | −$0.33 |
| Diluted shares (average) | 10m | 24m | 25m | 29m | 33m | 34m | 38m | 41m | 43m | 44m |
| EBITDA | −16 | −11 | −35 | −37 | −50 | −56 | −42 | −31 | −17 | −11 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 40 | 49 | 47 | 49 | 49 | 56 | 53 | 56 |
| Cost of revenue | 8 | 10 | 10 | 10 | 10 | 12 | 11 | 11 |
| Gross profit | 32 | 39 | 38 | 39 | 39 | 45 | 42 | 45 |
| Research and development | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 5 |
| Selling and marketing | 27 | 31 | 31 | 31 | 30 | 33 | 33 | 34 |
| General and administrative | 8 | 9 | 10 | 11 | 10 | 10 | 10 | 10 |
| Operating income | −8 | −5 | −7 | −7 | −5 | −2 | −5 | −5 |
| Interest expense | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | −7 | −4 | −7 | −6 | −5 | −2 | −4 | −4 |
| Diluted EPS | −$0.16 | −$0.11 | −$0.15 | −$0.14 | −$0.11 | −$0.04 | −$0.10 | −$0.09 |
| EBITDA | −7 | −4 | −6 | −6 | −4 | −1 | −3 | −3 |
Compare with peers
- Treace Medical Concepts, Inc. income statement
- Lakeland Industries Inc income statement
- Establishment Labs Holdings Inc. income statement
- Cerus Corp income statement
- Lemaitre Vascular Inc income statement
Head to head: SIBN vs TMCILAKE vs SIBNESTA vs SIBN
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies